In a report issued on January 18, Geoff Meacham from Barclays maintained a Hold rating on Bristol Myers (BMY), with a price target of $53. The company’s shares closed on Friday at $50.12.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of 5.1% and a 54.7% success rate. Meacham covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Bausch Health Companies Inc, and Vertex Pharmaceuticals.
Currently, the analyst consensus on Bristol Myers is a Moderate Buy with an average price target of $59.33, a 18.4% upside from current levels. In a report issued on January 4, Edward Jones also downgraded the stock to Hold.
See today’s analyst top recommended stocks >>
Bristol Myers’ market cap is currently $81.81B and has a P/E ratio of 56.95. The company has a Price to Book ratio of 6.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
